News

  • 10 December 2018

    Novartis reports new positive data from MONALEESA trials

    Novartis has reported positive results from three pivotal Phase III MONALEESA trials evaluating kisqali (ribociclib) plus endocrine therapy in combination with endocrine therapy alone for the treatment of human epidermal...

  • 7 December 2018

    Centrexion completes enrolment in Phase III CNTX-4975 trial

    Centrexion Therapeutics has completed patient enrolment ahead of schedule in the Phase III VICTORY-1 trial assessing the safety and efficacy of CNTX-4975 for the treatment of individuals with moderate-to-severe knee...

  • 6 December 2018

    Exelixis and Ipsen start COSMIC-312 trial for advanced HCC

    Exelixis and Ipsen have begun the Phase III COSMIC-312 trial of cabozantinib (cabometyx) in combination with atezolizumab (tecentriq) against sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC).